Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
357 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Financiado por un miembro del IRDiRC = 
; Miembro de una ERN = 
Ensayo(s) clínico(s) nacional(es)
ESTADOS UNIDOS
Maryland
BETHESDA
CALGB 10603: A Phase III randomized, double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (High-Dose Cytarabine) chemotherapy + Midostaurin (PKC412) or Placebo in newly diagnosed patients < 60 years of age with FLT3 mutated Acute Myeloid Leukemia (AML)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A phase I/II multicentre study of autologous stem cell transplantation followed by nonmyeloablative allogeneic stem cell transplantation for patients with relapsed or refractory Lymphoma -DE
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Estudio de fase III aleatorizado y doble ciego de la quimioterapia de inducción (daunorubicina/citarabina) y consolidación (citarabina en dosis altas) + midostaurina (PKC412) (ind nº 101261) o placebo en pacientes menores de 60 años diagnosticados de novo de leucemia mieloide aguda (LMA) con mutación en FLT3 (finalizado)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
MPD-RC 112 (Pegasys): Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia (Phase III) - UK
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) - US
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
PEGHU-Phase3: Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia (Phase III) - DE - Prematurely Ended
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
CALGB 10603: A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML) - UK
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas (Phase II)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients ( 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF) - US
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC) - US
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma - IE
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations - IE
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma - FR
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 (MK-1775) in Combination With Cisplatin and Radiation in Cervical Cancer (10041848, 10008224, 10008328)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Randomized Phase 2 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver (terminated)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab in Treating Patients With High-Risk Non-Metastatic Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Malignant peripheral nerve sheath tumor
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcinoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Avelumab for People With Recurrent Respiratory Papillomatosis
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Sunitinib
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
PVSRIPO With/Without Lomustine
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Brentuximab Vedotin, Cyclosporine, and Verapamil in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) Injection in Kaposi Sarcoma (KS)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Hyperthermic Intraperitoneal Chemotherapy or Intraperitoneal Chemotherapy in Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (suspended)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Cytarabine and Idarubicin or Decitabine in Treating Older Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Adjuvant Avelumab in Merkel Cell Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
TAS-102 in Treating Advanced Biliary Tract Cancers
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Lenvatinib Mesylate and Pembrolizumab in Treating Patients With Metastatic or Recurrent Gastric or Gastroesophageal Cancer
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age greater or equal to 60 With Poor Prognosis Acute Myeloid Leukemia (AML)
Institution: Information not provided - US
Ensayo(s) clínico(s) multinacional(es)
ESTADOS UNIDOS
California
ARCADIA
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)
Children's Oncology Group
ESTADOS UNIDOS
California
ARCADIA
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
ESTADOS UNIDOS
California
ARCADIA
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Children's Oncology Group
ESTADOS UNIDOS
California
ARCADIA
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma
Children's Oncology Group
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Maryland
BETHESDA
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
National Institute of Child Health and Human Development (NICHD)
National Cancer Institute (NCI)
ESTADOS UNIDOS
Massachusetts
BOSTON
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
Dana-Farber Cancer Institute Boston
Dana-Farber Cancer Institute
ESTADOS UNIDOS
New York
NEW YORK
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Icahn School of Medicine at Mount Sinai
ESTADOS UNIDOS
Pennsylvania
PHILADELPHIA
ESTADOS UNIDOS
Pennsylvania
PHILADELPHIA
Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
RADIATION THERAPY ONCOLOGY GROUP
ESTADOS UNIDOS
Pennsylvania
PHILADELPHIA
Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
RADIATION THERAPY ONCOLOGY GROUP
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
SEATTLE